top of page

ASGCT 2026: Ascidian Therapeutics is presenting initial human safety data from its RNA exon editing platform in a Stargardt disease trial

  • 31 minutes ago
  • 1 min read

CSO Robert Bell describes the advantages of RNA exon editing he sees over DNA editing, and walks us through the safety data. With that in hand, which was in adult patients, the company is moving forward in pediatric patients.




Coverage brought to you by



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

​

​Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

bottom of page